InflaRx NV
inflarx.deWhat Do They Do?
Develops and commercializes medicines that target inflammation, including an antibody for hospitals and an oral drug candidate for patients with autoimmune and other inflammatory diseases.
20-F for FY2025, filed Mar 20, 2026We are a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, an inherent part of the…View ↗
To explore the full potential of our anti-C5a/C5aR technologies, we are clinically developing our lead product candidate, izicopan…View ↗
Vilobelimab has been tested in critically ill COVID-19 patients, for which we concluded a double-blinded, placebo controlled, multicenter…View ↗
Who Are Their Customers?
Hospitals in the U.S. can order GOHIBIC.
20-F for FY2025, filed Mar 20, 2026Vilobelimab has been tested in critically ill COVID-19 patients, for which we concluded a double-blinded, placebo controlled, multicenter…View ↗
Loading...
